273 related articles for article (PubMed ID: 33674239)
21. Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas.
Johnson PC; Abramson JS
Leuk Lymphoma; 2020 Nov; 61(11):2561-2567. PubMed ID: 32611216
[TBL] [Abstract][Full Text] [Related]
22. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
23. Comments on "Cost of decentralized CAR T cell production in an academic non-profit setting".
Schmitt M; Schmitt A; Thalheimer M; Dreger P; Müller-Tidow C
Int J Cancer; 2021 Jan; 148(2):514-515. PubMed ID: 32798335
[No Abstract] [Full Text] [Related]
24. Importance of CAR-T cell therapy monitoring using high-throughput assays.
Pratt CB; Alexander M
Drug Discov Today; 2022 Oct; 27(10):103310. PubMed ID: 35760281
[TBL] [Abstract][Full Text] [Related]
25. Manufacturing chimeric antigen receptor T cells: issues and challenges.
Roddie C; O'Reilly M; Dias Alves Pinto J; Vispute K; Lowdell M
Cytotherapy; 2019 Mar; 21(3):327-340. PubMed ID: 30685216
[TBL] [Abstract][Full Text] [Related]
26. Future supply chains enabled by continuous processing--opportunities and challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
Srai JS; Badman C; Krumme M; Futran M; Johnston C
J Pharm Sci; 2015 Mar; 104(3):840-9. PubMed ID: 25631279
[TBL] [Abstract][Full Text] [Related]
27. Quality risk management of the chimeric antigen receptor T cell pharmaceutical circuit in one of the first qualified European centers.
Talarmin C; Kerob S; Cartier F; Madelaine I; Mukenyi S; Schwartz E; Boissel N; Baruchel A; Thieblemont C; Parquet N; Brignier A; Lesprit E; Desproges A; Magdelonnette L; Larghero J; Mebarki M
Cytotherapy; 2020 Dec; 22(12):792-801. PubMed ID: 32732084
[TBL] [Abstract][Full Text] [Related]
28. Development of CAR-T cell therapy for B-ALL using a point-of-care approach.
de Macedo Abdo L; Barros LRC; Saldanha Viegas M; Vieira Codeço Marques L; de Sousa Ferreira P; Chicaybam L; Bonamino MH
Oncoimmunology; 2020; 9(1):1752592. PubMed ID: 32363126
[TBL] [Abstract][Full Text] [Related]
29. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
30. Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective.
Ramakrishnan S; Kumar J; Datta SS; Radhakrishnan V; Nair R; Chandy M
Front Oncol; 2022; 12():1062296. PubMed ID: 36531042
[TBL] [Abstract][Full Text] [Related]
31. Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic function.
Caruso HG; Tanaka R; Liang J; Ling X; Sabbagh A; Henry VK; Collier TL; Heimberger AB
J Neurooncol; 2019 Dec; 145(3):429-439. PubMed ID: 31686330
[TBL] [Abstract][Full Text] [Related]
32. [CAR-T cells: Lymphocytes that express a chimeric antigen receptor].
Chabannon C; Bouabdallah R; Fürst S; Granata A; Saillard C; Vey N; Mokart D; Fougereau E; Lemarie C; Mfarrej B; Blaise D; Calmels B
Rev Med Interne; 2019 Aug; 40(8):545-552. PubMed ID: 30686549
[TBL] [Abstract][Full Text] [Related]
33. What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings.
Ten Ham RMT; Hövels AM; Hoekman J; Frederix GWJ; Leufkens HGM; Klungel OH; Jedema I; Veld SAJ; Nikolic T; Van Pel M; Zwaginga JJ; Lin F; de Goede AL; Schreibelt G; Budde S; de Vries IJM; Wilkie GM; Dolstra H; Ovelgönne H; Meij P; Mountford JC; Turner ML; Hoefnagel MHN
Cytotherapy; 2020 Jul; 22(7):388-397. PubMed ID: 32414635
[TBL] [Abstract][Full Text] [Related]
34. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
Hunter BD; Rogalski M; Jacobson CA
Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
[No Abstract] [Full Text] [Related]
35. Advancing autologous CAR T-cell therapy through real-time patient health data integration: a simulation-based approach.
Tseng CY; Wang K; Lin LH; Zhang C; White CC; Wang B
Cytotherapy; 2024 May; ():. PubMed ID: 38795115
[TBL] [Abstract][Full Text] [Related]
36. Manufacturing Cell and Gene Therapies: Challenges in Clinical Translation.
Lee NK; Chang JW
Ann Lab Med; 2024 Jul; 44(4):314-323. PubMed ID: 38361427
[TBL] [Abstract][Full Text] [Related]
37. CAR-T cell therapy in India requires a paradigm shift in training, education and health care processes.
Ravindranath A; Dubey A; Suresh S; Chaudhuri G; Chirmule N
Cytotherapy; 2022 Feb; 24(2):101-109. PubMed ID: 34753677
[TBL] [Abstract][Full Text] [Related]
38. Critical care utilisation for patients receiving chimeric antigen receptor (CAR) T cell therapy in the UK.
Pirani T; Wilson A; Brealey D; Low R; O'Neill S; Le J; Jhanji S; Bangash MN; Mathew A; Wright C; Latif AL; Irvine D; Kasipandian V; Singh N; Saha R; Metaxa V
Br J Anaesth; 2024 May; 132(5):1004-1006. PubMed ID: 38521658
[No Abstract] [Full Text] [Related]
39. Approaches of T Cell Activation and Differentiation for CAR-T Cell Therapies.
Schwab RD; Bedoya DM; King TR; Levine BL; Posey AD
Methods Mol Biol; 2020; 2086():203-211. PubMed ID: 31707678
[TBL] [Abstract][Full Text] [Related]
40. Chimeric Antigen Receptor T-Cell Therapies: Barriers and Solutions to Access.
Mikhael J; Fowler J; Shah N
JCO Oncol Pract; 2022 Dec; 18(12):800-807. PubMed ID: 36130152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
